AbbVie has announced new clinical data from its antibody-drug conjugate (ADC) platform, reinforcing its commitment to advancing targeted therapies for solid tumours. The data will be presented at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, taking place from 17 to 21 October.
The company’s investigational ADCs, including telisotuzumab adizutecan (Temab-A) and ABBV-706, demonstrated encouraging results across pancreatic, colorectal and other solid tumour types. AbbVie also shared updates on Emrelis (telisotuzumab vedotin), which is already approved for certain indications.
Daejin Abidoye, Vice President, Therapeutic Area Head, Oncology, Solid Tumour and Haematology, said: “We are excited to share new data from our growing ADC portfolio at ESMO 2025, including promising results from our investigational therapies telisotuzumab adizutecan and ABBV-706.
“These data reinforce our commitment to advancing novel targeted therapies for patients with difficult-to-treat cancers.”
The company highlighted that its ADCs are designed to deliver potent cytotoxic agents directly to cancer cells, potentially improving efficacy while limiting systemic toxicity. The phase 1 and phase 2 studies presented include data on safety, tolerability and preliminary efficacy.
AbbVie explained that the results support further development of its ADC candidates and underscore the potential of targeted approaches in oncology. The company’s pipeline continues to expand, with multiple ADCs in various stages of clinical development.
Abidoye added: “We remain focused on developing innovative therapies that have the potential to transform standards of care and improve outcomes for patients.”
The data presented at ESMO 2025 are expected to inform future clinical strategies and regulatory discussions, as AbbVie aims to strengthen its position in the oncology space.
